Inficure Bio a life science company focused on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions co-presented with CymaBay Therapeutics positive data at the American Association for the study of Liver Diseases (AASLD) using the company’s proprietary NIF mouse model.
Inficure Bio, based in Umeå in northern Sweden, has recently been granted a patent in the United States for its unique preclinical model. At the same time a study describing the basics of the model has been accepted for publication in respected online journal Scientific Reports.
“We are delighted and anticipate that thanks to this attention we will strengthen our position in the market and expect even more customers to show interest in our model”, says Sofia Mayans, CEO of Inficure Bio.
Umeå-based life science company Inficure Bio is one of three companies from northern Sweden chosen to present their business cases at ‘Mötesplats Stockholm – The Great Northern Capital Connect’ in early 2021.
Swedish Inficure Bio has signed an agreement with a publicly listed US biopharmaceutical company that develops drugs for several chronic and life-threatening diseases.
“We will now begin testing the effects of their drug substances in our unique model. The company is world-leading in drug development, so this recognition is significant for us,” says Inficure Bio’s CEO, Sofia Mayans.
Umeå-based Inficure Bio is expanding again, as yet another employee is hired to meet the growing demand for the company’s products.
“Things are going really well for us right now and it feels like the perfect time to expand our team,” says Sofia Mayans, CEO of Inficure Bio.
When Umeå’s big business gala was held on November 7, three of twelve awards went to life science.
“Previously, life science had a relatively hidden role in Umeå – but during this year’s Umeågala we have proven that we are an industry that has great potential”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.
Umeå-based Inficure Bio signed the biggest deal in the company’s history back in April. Now they have signed a new deal – which is twice as large.
“This is a fantastic opportunity for us. Deals like this demonstrate that our international credibility is increasing”, says Sofia Mayans, CEO of Inficure Bio.
Life science company Inficure Bio attract millions in new funding round.
“Attracting new investment allows us to move faster. We have lots of potential customers and we want to launch new applications for our product”, says Sofia Mayans, CEO of Umeå-based Inficure Bio.
Umeå-based life science company Inficure Bio has appointed Lena Söderström, who was previously in charge at stock exchange listed company Senzime, as its new chairman of the board of directors.
Umeå-based life science company Inficure Bio has just won the largest contract in its history.
“It feels incredible! The more large customers we get the greater our credibility becomes. This agreement is a real feather in our cap”, says Sofia Mayans, CEO of Inficure Bio.
Life science company Inficure Bio has been awarded millions by Vinnova to support the company’s development of a model that will help create new treatments for fibrosis.
“This money is incredibly important to us. Thanks to this investment we can now finish developing a new product”, says Sofia Mayans, CEO of Inficure Bio.